Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hitCNBC • 10/30/25
Merck posts higher third-quarter sales as Keytruda growth offsets drop from GardasilReuters • 10/30/25
Dow Jones Stock Merck Tops Expectations, But Gardasil Challenges RemainInvestors Business Daily • 10/30/25
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial ResultsBusiness Wire • 10/30/25
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular CarcinomaBusiness Wire • 10/29/25
European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)Business Wire • 10/29/25
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earningsCNBC • 10/28/25
Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following NephrectomyBusiness Wire • 10/28/25
Merck and Eisai Announce WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell CarcinomaBusiness Wire • 10/28/25
JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?Zacks Investment Research • 10/27/25
Merck (MRK) Q3 Earnings Preview: What You Should Know Beyond the Headline EstimatesZacks Investment Research • 10/27/25
U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH StudyBusiness Wire • 10/27/25